ResearcherAmsterdam UMC Location University of AmsterdamNo recent work listed
Heinz‐Josef Klümpen
Matched on ORCID iD 0000-0002-7290-1823; OpenAlex author ID A5052741985. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper
Papers 3
- Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. First author DOI 10.1007/s00280-015-2730-y↗
- A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced panc… Co-author DOI 10.1007/s10637-012-9802-1↗
- mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. Co-author DOI 10.1200/jco.2010.32.7825↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dick J. Richel · 3 shared papers, 2011–2015 · strength 0.13
- Paper Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. DOI 10.1007/s00280-015-2730-y↗
- Paper A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and cap… DOI 10.1007/s10637-012-9802-1↗
- Paper mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. DOI 10.1200/jco.2010.32.7825↗
- Johanna W. Wilmink · 2 shared papers, 2013–2015 · strength 0.10
- Paper Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. DOI 10.1007/s00280-015-2730-y↗
- Paper A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and cap… DOI 10.1007/s10637-012-9802-1↗
- Sil Kordes · 2 shared papers, 2013–2015 · strength 0.10
- Paper Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. DOI 10.1007/s00280-015-2730-y↗
- Paper A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and cap… DOI 10.1007/s10637-012-9802-1↗
- Jan H.M. Schellens · 1 shared paper, 2015 · strength 0.06
- C. Arnold Spek · 1 shared paper, 2011 · strength 0.02
- G. Johan A. Offerhaus · 1 shared paper, 2011 · strength 0.02
- Roeland F. de Wilde · 1 shared paper, 2011 · strength 0.02
- Karla C. S. Queiroz · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.